^
    2d
    A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date • Minimal residual disease
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • NavDx®
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    3d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=390, Completed, Merck Sharp & Dohme LLC | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    3d
    GlitIpNi: A phase IB clinical trial on neoadjuvant and intraoperative intracranial nadministration of triple immune checkpoint blockade plus myeloid dendritic ncells in patients with recurrent high-grade glioma (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Universitair Ziekenhuis Brussel | Phase classification: P1/2 --> P1
    Phase classification • Checkpoint inhibition
    |
    IDH wild-type
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw)
    4d
    LAG-BOOST: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=72, Recruiting, University of Oklahoma | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    10d
    RELATIVITY-069: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=5, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=68 --> 5 | Trial completion date: Jul 2028 --> Dec 2025 | Trial primary completion date: Jul 2028 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    15d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=494, Recruiting, Melanoma Institute Australia | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    16d
    Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (clinicaltrials.gov)
    P2, N=70, Recruiting, Thomas Jefferson University | N=35 --> 70
    Enrollment change
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    17d
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    17d
    A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    17d
    Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma (2024-519208-29-00)
    P1/2, N=126, Not yet recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P1/2 trial
    |
    pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    23d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • axitinib • tiragolumab (RG6058) • tobemstomig (RG6139)
    23d
    CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=27, Completed, Jose Lutzky, MD | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)